CFI-402257 clinical trials
Also written CFI-402257.
How each study uses CFI-402257 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the CFI-402257 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- CFI-402257
- 4
Studies by the year they started
4 studies that test it; most in 2016 (1)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2019 | 1 |
| 2022 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 3
Canadian Cancer Trials Group (2) · Treadwell Therapeutics, Inc (1) · University Health Network, Toronto (1)
Often tested with
Tested in the same studies.
Lunresertib (1) · Niraparib (1) · Camonsertib (1) · Ocifisertib fumarate (1) · Sacituzumab govitecan (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses CFI-402257 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast CancerRecruitingPhase 2Canadian Cancer Trials GroupNCT05601440Written as CFI-402257How we know
- A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid TumorsCompletedPhase 1University Health Network, TorontoNCT02792465Written as CFI-402257How we know
- CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast CancerActive, not recruitingPhase 1/2Canadian Cancer Trials GroupNCT03568422Written as CFI-402257How we know
- CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast CancerActive, not recruitingPhase 1/2Treadwell Therapeutics, IncNCT05251714Written as CFI-402257How we know
Codes
What other systems call CFI-402257 · ClinicalTrials.gg INT000843
- MeSH (NLM) C000625147CFI-402257One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000625147 | CFI-402257 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.